Page last updated: 2024-08-21

thiazoles and Triple Negative Breast Neoplasms

thiazoles has been researched along with Triple Negative Breast Neoplasms in 24 studies

Research

Studies (24)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's18 (75.00)24.3611
2020's6 (25.00)2.80

Authors

AuthorsStudies
Cheung, YM; Cromwell, GE; McDonnell, ME; Min, L; Tolaney, SM1
Adalsteinsson, V; Batalini, F; Cantley, LC; D'Andrea, A; Eismann, J; Konstantinopoulos, PA; Matulonis, UA; Mayer, EL; Polak, M; Shapiro, GI; Swisher, EM; Tayob, N; Winer, EP; Wulf, GM; Xiong, N1
Blackley, EF; Bujak, AZ; Callahan, J; Dawson, SJ; Francis, PA; Ftouni, S; Hicks, RJ; Ko, YA; Lee, CK; Lo, LL; Loi, S; Luen, SJ; Moodie, K; Savas, P; Silva, MJ; van Geelen, CT; Wein, L; Weng, CF; Yeung, MM1
Chaudhry, AR; Denvir, J; Fan, J; Piwarski, SA; Primerano, DA; Salisbury, TB; Thompson, C1
Irurzun-Arana, I; McDonald, TO; Michor, F; Trocóniz, IF1
Bakacsy, L; Barta, A; Fazakas, C; Hohmann, J; Kele, Z; Krizbai, IA; Kúsz, N; Stefkó, D; Szepesi, Á; Vasas, A; Wilhelm, I1
Bergmeier, SC; Burdick, MM; Champa, ZJ; Deosarkar, SP; Goetz, DJ; Lanier, OL; McCall, KD; Noori, MS; O'Brien, JD; Qi, C; Schwartz, FL1
Chen, H; Du, Y; Li, Q; Ling, H; Qi, H; Shi, X; Song, L; Zhang, L; Zhang, Y1
Bai, Y; Cheng, K; Sun, H; Wang, X; Yang, Z; Zhang, G; Zou, W1
Boyle, K; Brantley, EJ; Campbell, PS; Daly, D; Mavingire, N; McLean, L; Rowland, LK; Thorne, G; Unternaehrer, J; Whang, S; Wooten, JV; Zylstra, D1
Fu, J; Lin, Y; Liu, C; Lu, G; Lu, Z; Wan, X1
Han, ES; Mortimer, J; Wen, W; Xing, Q; Yan, J; Yim, JH; Yost, SE; Yuan, Y1
Guo, H; Hartkamp, J; Krämer, OH; Lüscher, B; Treude, F1
Roux, PP; Shin, S; Tcherkezian, J; Vallabhapurapu, S; Wolgamott, L; Yoon, SO; Yu, Y1
Boerner, J; Gartner, E; Kim, EM; Mueller, K1
Baxter, RC; de Silva, HC; Lin, MZ; Martin, JL; Scott, CD1
Cai, Y; Jiang, W; Peng, R; Shi, Y; Wu, G; Xia, Q1
Abdissa, TT; Johnson, GL; Scott, JE; Tarpley, M1
Blijlevens, M; Frangou, C; Guo, J; Li, YW; Nowak, NJ; Shen, H; Wilson, KE; Yang, N; Zhang, J1
Feng, X; Liu, Q; Mai, B; Wang, P; Wang, X; Zhang, T1
Chen, ZJ; Du, J; Liang, WT; Liu, H; Liu, HL; Liu, T; Lu, LL; Wang, HS; Wei, WD; Wu, YM; Yang, XL1
Chen, ZJ; Du, J; Huang, HB; Jiang, GM; Liang, SW; Liu, Q; Wang, HS; Wu, YM; Zhang, KS; Zhou, Y1
Chowdhury, N; Doddapaneni, R; Patel, K; Singh, M1
Bansal, N; Bosch, A; Cubedo, E; Farias, E; Fishel, M; Jones, JW; Kane, M; Leibovitch, B; Pereira, L; Pierzchalski, K; Waxman, S; Yu, J; Zelent, A1

Trials

2 trial(s) available for thiazoles and Triple Negative Breast Neoplasms

ArticleYear
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Female; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Thiazoles; Triple Negative Breast Neoplasms

2022
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.
    Cancer discovery, 2022, 09-02, Volume: 12, Issue:9

    Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Mutation; Phosphatidylinositol 3-Kinases; Receptor, ErbB-2; Thiazoles; Triple Negative Breast Neoplasms

2022

Other Studies

22 other study(ies) available for thiazoles and Triple Negative Breast Neoplasms

ArticleYear
Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
    Breast cancer research and treatment, 2022, Volume: 192, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Triple Negative Breast Neoplasms

2022
The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.
    Biochemical pharmacology, 2020, Volume: 174

    Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Jagged-1 Protein; Ligands; MCF-7 Cells; Receptor, Notch1; Receptors, Aryl Hydrocarbon; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms

2020
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance.
    Cancer research, 2020, 08-15, Volume: 80, Issue:16

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinolines; Software; Thiazoles; Triple Negative Breast Neoplasms

2020
Gerardiins A-L and Structurally Related Phenanthrenes from the Halophyte Plant
    Journal of natural products, 2020, 10-23, Volume: 83, Issue:10

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Magnoliopsida; Mice; Molecular Structure; Phenanthrenes; Plant Extracts; Salt-Tolerant Plants; Tetrazolium Salts; Thiazoles; Triple Negative Breast Neoplasms

2020
Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells.
    European journal of pharmacology, 2017, May-15, Volume: 803

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Interleukin-8; Methimazole; NF-kappa B p50 Subunit; Thiazoles; Thiones; Transcription Factor RelA; Triple Negative Breast Neoplasms

2017
The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
    European journal of medicinal chemistry, 2017, Aug-18, Volume: 136

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ERRalpha Estrogen-Related Receptor; Female; Humans; Molecular Structure; Nitriles; Receptors, Estrogen; Structure-Activity Relationship; Thiazoles; Triple Negative Breast Neoplasms

2017
PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer.
    Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:8

    Topics: Antineoplastic Agents; B7-H1 Antigen; Carboplatin; Chemokine CXCL5; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; MCF-7 Cells; Myeloid-Derived Suppressor Cells; Phosphorylation; Signal Transduction; T-Lymphocytes; Thiazoles; Triple Negative Breast Neoplasms; Tumor Microenvironment

2017
Putative tumor suppressor cytoglobin promotes aryl hydrocarbon receptor ligand-mediated triple negative breast cancer cell death.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:4

    Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Caspase 3; Cathepsin B; Cell Line, Tumor; Cytoglobin; Female; Humans; Ligands; Mice; Mice, Nude; Receptors, Aryl Hydrocarbon; Thiazoles; Transfection; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2019
pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer.
    Drug delivery, 2019, Volume: 26, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Cell-Penetrating Peptides; Diamines; Drug Carriers; Drug Liberation; Erlotinib Hydrochloride; Female; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oligopeptides; Receptors, Notch; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019
Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Scientific reports, 2019, 05-17, Volume: 9, Issue:1

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Synergism; Enzyme Inhibitors; Female; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2019
PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.
    Scientific reports, 2019, 06-19, Volume: 9, Issue:1

    Topics: Caspase 8; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Neoplasm Proteins; Receptors, Thrombin; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases

2019
Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1.
    Oncogene, 2014, Mar-27, Volume: 33, Issue:13

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Cycle Proteins; Cell Growth Processes; Enzyme Inhibitors; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Nude; Peptide Initiation Factors; Phosphoproteins; Phosphorylation; Protein Binding; Protein Biosynthesis; Random Allocation; Thiazoles; Triple Negative Breast Neoplasms; Urea; Xenograft Model Antitumor Assays

2014
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    The Journal of surgical research, 2013, Volume: 185, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cetuximab; Cisplatin; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Humans; Neoplasm Invasiveness; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Triple Negative Breast Neoplasms

2013
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:2

    Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2014
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    International journal of oncology, 2014, Volume: 44, Issue:3

    Topics: BRCA1 Protein; CDC2 Protein Kinase; Cell Line, Tumor; DNA Damage; Female; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolines; Thiazoles; Triple Negative Breast Neoplasms

2014
Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Triple Negative Breast Neoplasms

2014
Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets.
    Oncotarget, 2014, Dec-15, Volume: 5, Issue:23

    Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Flow Cytometry; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins; Transcriptome; Transduction, Genetic; Transfection; Triple Negative Breast Neoplasms

2014
Glycolytic inhibitors 2-deoxyglucose and 3-bromopyruvate synergize with photodynamic therapy respectively to inhibit cell migration.
    Journal of bioenergetics and biomembranes, 2015, Volume: 47, Issue:3

    Topics: Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxyglucose; Drug Synergism; Fluorescent Antibody Technique; Glycolysis; Humans; Microscopy, Electron, Scanning; Photochemotherapy; Pyruvates; Tetrazolium Salts; Thiazoles; Triple Negative Breast Neoplasms

2015
Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Movement; Dose-Response Relationship, Drug; Drug Inverse Agonism; Epithelial-Mesenchymal Transition; ERRalpha Estrogen-Related Receptor; Female; Fibronectins; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Lung Neoplasms; MCF-7 Cells; Mice, Nude; Middle Aged; Nitriles; Promoter Regions, Genetic; Protein Binding; Receptors, Estrogen; Retrospective Studies; RNA Interference; Signal Transduction; Thiazoles; Time Factors; Transfection; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2015
Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
    Oncotarget, 2016, Mar-15, Volume: 7, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ERRalpha Estrogen-Related Receptor; Female; Humans; Mice; Nitriles; Reactive Oxygen Species; Receptors, Estrogen; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2016
Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
    Experimental cell research, 2016, 08-01, Volume: 346, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Coumarins; Docetaxel; Drug Carriers; Enzyme Activation; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Liposomes; Mice; Microtubules; Nanoparticles; Noscapine; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Polymerization; Staining and Labeling; Taxoids; Thiazoles; Triple Negative Breast Neoplasms; Tubulin; Xenograft Model Antitumor Assays

2016
Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Animals; Antineoplastic Agents; Benzoates; Carcinogenesis; Cell Line, Tumor; Female; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Receptors, Retinoic Acid; Repressor Proteins; Sin3 Histone Deacetylase and Corepressor Complex; Tetrahydronaphthalenes; Thiazoles; Triple Negative Breast Neoplasms

2016